• Tue news: Novo looks to speed up India Wegovy launch. 4 revelations from MN’s 340B transparency report. 4 oral GLP-1R’s in dev. Roche autoimmune partnership. Gilead-Tubulis alliance. See more on our front page

Terlipressin take the job Yeah or Nay?

Quote
anonymous said:
Not getting the job should not bother you. They have built up the team for positioning but come June/July there will be new board/leadership in town and watch out. Cost cuts and MNK will sell the drug off if the deal comes through. Same with generics.
Looming recession, falling sales, high debt costs will bury this place and all companies for that matter that are over leveraged. Winter is coming for a lot of places with poor balance sheets.
Click to expand...
Jenn?
 






anonymous said:
Not getting the job should not bother you. They have built up the team for positioning but come June/July there will be new board/leadership in town and watch out. Cost cuts and MNK will sell the drug off if the deal comes through. Same with generics.
Looming recession, falling sales, high debt costs will bury this place and all companies for that matter that are over leveraged. Winter is coming for a lot of places with poor balance sheets.
Click to expand...

MNK is stuck with Generics, or at least the opioids, for a few years due to the bankruptcy settlement. There’s still plenty to sell off, and it would not be a surprise if they unite Generics with Brands again to save money. If MNK can survive long enough to pay off the opioids trust fund, I expect the new board would then sell off the entire company.
 


















































































































Top Bottom
Back
Quote